Who Invented the First Cochlear Implant?

The first cochlear implant was placed by French surgeon Charles Eyriès in 1957, working alongside physicist André Djourno, who had designed the electrical stimulation device. Their collaboration in Paris produced the earliest known instance of an electronic device directly stimulating a deaf person’s auditory nerve to create sound perception. But calling any single person “the inventor” oversimplifies a technology that took decades, multiple independent teams across three continents, and fierce scientific rivalries to reach the form we recognize today.

The Earliest Spark of the Idea

Long before anyone dreamed of an implantable hearing device, scientists knew that electricity could produce auditory sensations. The Italian physicist Alessandro Volta, better known for inventing the electric battery, is credited as the first person to stimulate the ear with electricity. In June 1800, he presented the results of his experiments to the Royal Society of London, describing a crackling or bubbling sound when he applied electrical current to metal rods inserted into his own ears.¹ The sensation was unpleasant enough that Volta chose not to repeat it, but his observation planted a seed: the auditory system could respond to electrical signals, not just sound waves.

Over the next century and a half, various researchers experimented with electrical stimulation of hearing, but no one managed to turn these observations into a practical device for deaf people. The technology simply was not ready. Electrodes were crude, electronics were bulky, and understanding of the auditory nerve was rudimentary. It took the mid-twentieth century, with its transistors and miniaturized components, to make an implantable device even conceivable.

Djourno and Eyriès in Paris

In the 1950s, André Djourno, a physicist and electrophysiologist, had been working on ways to stimulate nerves electrically. Charles Eyriès was an otolaryngologist treating a patient who had lost hearing after surgery. Djourno suggested they try directly stimulating the auditory nerve with an induction coil. In 1957, Eyriès implanted the device, and the patient reported hearing sounds for the first time in years, including rudimentary perception of words and environmental noises.²

The device was primitive by any modern standard. It could not deliver anything close to normal speech understanding. The patient could distinguish some rhythmic patterns and a few words, but the experience was more proof-of-concept than practical hearing restoration. Still, Djourno and Eyriès had demonstrated something revolutionary: you could bypass the damaged inner ear entirely and feed electrical signals directly to the auditory nerve. The partnership was short-lived, however. The two men reportedly had a falling out, and Djourno’s contributions were largely overlooked outside France for years. This early work became a footnote in the English-language literature, even though it directly inspired the American researchers who came next.

William House and the American Single-Channel Implant

Word of the French experiments crossed the Atlantic, and in Los Angeles, an ear surgeon named William House took notice. House was already known for pushing boundaries in otology, and he saw the French work as something worth pursuing aggressively. In 1961, House and neurosurgeon John Doyle performed the first cochlear implant surgery in the United States.³ Their device was a single-channel electrode, meaning it delivered one stream of electrical stimulation rather than targeting different regions of the cochlea.

House faced enormous resistance from the medical establishment. Many audiologists and otologists believed that a single electrode could never reproduce the complexity of human hearing and that implanting anything into the delicate cochlea was reckless. Some critics compared the idea to quackery. Despite the pushback, House persisted, refining his single-channel device throughout the 1960s and 1970s.⁴ His implant could not deliver clear speech understanding, but it gave profoundly deaf recipients awareness of environmental sounds, rhythm, and lip-reading cues that many users found genuinely helpful. For people living in total silence, even that limited input was life-changing.

House’s single-channel design eventually became the first cochlear implant approved by the U.S. Food and Drug Administration, in 1984, for adults. That approval was a watershed moment: it validated the entire concept of cochlear implantation as a legitimate medical treatment rather than a fringe experiment.

Other Early Experimenters at Stanford and UCSF

House was not the only American researcher pursuing the idea. At Stanford University, otolaryngologist Blair Simmons and engineer Robert White took a different approach. In 1962, they conducted stimulation tests through a posterior craniotomy, placing an electrode on the acoustic nerve. Then, in May 1964, Simmons and White placed a permanent six-channel electrode through the promontory and vestibule directly into the modiolus, the central axis of the cochlea.³ Their work demonstrated that multiple electrodes, each stimulating a different region of the cochlea, could produce different pitch perceptions. This was an important piece of evidence for the multi-channel approach that would eventually win out.

Meanwhile, the published results from these electrode experiments showed that a person deaf to acoustic stimulation could perceive auditory sensations through permanently implanted electrodes.⁵ At the University of California, San Francisco, Robin Michelson, Robert Schindler, and Michael Merzenich took the next step by conducting clinical trials on a cohort of patients in 1970 and 1971, moving the technology from one-off experimental surgeries toward systematic testing.³ These UCSF researchers would go on to play major roles in developing multi-channel implants and establishing the scientific rigor that regulators would eventually demand.

Graeme Clark and the Multi-Channel Revolution

The cochlear implant as most people know it today owes its existence largely to Graeme Clark, an Australian otolaryngologist who spent much of his career driven by a personal motivation: his father was deaf. Clark’s team in Melbourne developed a multi-channel implant that could deliver distinct electrical signals to different spots along the cochlea, mimicking how a healthy ear encodes different frequencies of sound at different locations. This was fundamentally different from House’s single-channel device. Instead of a single buzzy signal, Clark’s implant could produce something closer to the spectral richness of real speech.

Clark’s device, which became the Nucleus implant manufactured by Cochlear Limited, proved that recipients could understand open-set speech, meaning they could comprehend words and sentences they had never practiced, without lip-reading. That capability transformed the cochlear implant from a situational aid into a genuine hearing restoration tool. Clark’s invention has helped more than 300,000 people worldwide, with more than half of them being children.⁶ He also founded what is now the Bionics Institute in Melbourne to continue improving the technology through ongoing research.

The competition between single-channel and multi-channel designs lasted through the 1980s, and it was sometimes bitter. House’s supporters argued that his simpler device was safer and more practical. Clark and other multi-channel advocates argued that only their approach could achieve real speech understanding. The multi-channel camp ultimately prevailed in the scientific literature and in clinical outcomes, and single-channel devices were eventually phased out of production. But House’s role in proving the concept was surgically feasible and clinically useful remains widely acknowledged.

Why No Single Inventor Gets Full Credit

The cochlear implant is a case study in how complex medical devices rarely spring from a single mind. Volta established that electrical stimulation of the ear was possible. Djourno and Eyriès performed the first implant surgery. House proved the concept could work as a long-term clinical device in the face of fierce opposition. Simmons and White demonstrated multi-electrode stimulation. Clark engineered the multi-channel system that made real speech perception achievable. Each step depended on the ones before it, and each team worked independently enough that they deserve distinct recognition.

Cooperation between research groups and commercial manufacturers also accelerated the technology’s development.⁷ Companies like Cochlear Limited in Australia, Advanced Bionics in the United States, and MED-EL in Austria each brought different engineering approaches to market, and competition among them drove rapid improvements in electrode design, speech processing, and reliability. The device that exists today is the product of academic research, clinical daring, engineering innovation, and industrial scale-up working in parallel.

How the Deaf Community Responded

The cochlear implant was not universally welcomed. From the earliest days of its clinical use, many Deaf communities pushed back against the technology, particularly its use in children. In countries like France and the Netherlands, Deaf advocacy groups protested cochlear implantation of children, framing it not as medical progress but as part of a longer history of attempts to erase Deaf culture and sign language.⁸

The objection was not that the technology did not work. It was that defining deafness purely as a medical problem to be fixed ignored the existence of thriving Deaf communities with their own languages, schools, social networks, and cultural identity. When parents of deaf infants chose implantation, Deaf advocates argued, they were making an irreversible decision to steer a child away from Deaf culture before the child could have any say. This debate has not disappeared. It has evolved as implant outcomes have improved and as more nuanced approaches have emerged, with some families pursuing both implantation and sign language rather than treating them as mutually exclusive. But the tension between the medical model of deafness and the cultural model remains one of the most distinctive features of cochlear implant history.

Pediatric Implantation and the Push for Earlier Surgery

When cochlear implants first received regulatory approval, they were restricted to adults. The idea of operating on a child’s cochlea was considered too risky, and outcomes in very young children were unknown. Over time, research demonstrated that children implanted at younger ages developed better speech and language skills, because the brain’s auditory pathways are most adaptable in the first few years of life. This led to a steady lowering of the approved implantation age. The FDA eventually reduced its approved age to under nine months for certain devices, reflecting growing evidence that early implantation is both surgically safe and beneficial for language development.⁹

Pediatric implantation now accounts for a substantial share of all cochlear implant surgeries worldwide. The shift toward earlier intervention has been one of the most consequential developments in the field since Clark’s multi-channel breakthrough, and it has also intensified the cultural debate mentioned above, since the decision is made entirely by parents on behalf of a child too young to participate.

Two Ears Are Better Than One

For decades, most recipients received a cochlear implant in only one ear. Bilateral implantation, putting a device in both ears, was considered an unnecessary luxury. That view has changed substantially. Studies comparing bilateral to unilateral implantation found that having two implants improved sound localization, speech perception in noisy environments, and the recipient’s subjective experience of hearing, in both adults and children with severe to profound hearing loss.¹⁰ The ability to tell where a sound is coming from and to follow a conversation in a crowded room are things that people with normal hearing take for granted, and bilateral implants get closer to providing those abilities.

Coverage policies have been slower to catch up. Bilateral implantation costs roughly twice as much as unilateral, and in many healthcare systems, approval for the second implant requires additional justification. But the clinical trend is clearly moving toward bilateral as the standard of care, especially for children, whose language and social development benefit most from the fullest possible auditory input.

Preserving What Hearing Remains

Early cochlear implant surgery was not gentle. The goal was simply to get the electrode into the cochlea and make it work. If the patient had any residual hearing in the implanted ear, it was typically destroyed during the procedure. That trade-off was considered acceptable because candidates were profoundly deaf in both ears anyway.

As candidacy criteria have expanded to include people with some remaining low-frequency hearing, surgeons have developed techniques to protect the delicate structures inside the cochlea during electrode insertion. These “soft surgery” approaches include avoiding blood entry into the cochlea, using lubricants like hyaluronate, choosing thinner and more flexible electrode arrays, inserting them very slowly, and applying corticosteroids to reduce inflammation.¹¹ The aim is to combine electrical stimulation for high-frequency sounds the person cannot hear with preserved natural hearing for low frequencies they still can.¹²

Research into which specific surgical details matter most is ongoing. Fully opening the round window membrane, using a straight electrode array, inserting slowly, and administering corticosteroids have all been associated with higher rates of hearing preservation.¹³ This area of the field represents a significant philosophical shift: the cochlear implant is no longer a last resort for people with no hearing at all. It is increasingly a tool for people across a wider spectrum of hearing loss, and the surgery itself is becoming more refined to match that broader role.